Evidence map›Paper›PMID 41188337›Full record

ArticleScientific reports2025

Therapeutic effects of conditioned medium of immortalized dental pulp stem cells from human exfoliated deciduous teeth against experimental autoimmune neuritis.

Hideaki Hasegawa, Eri Sakamoto, Aruma Watanabe, Natsuki Yamaguchi, Eri Horio, Jukito Sonoda, Miu Yamagishi, Satomi Miyakawa, Fumihiro Murakami, Yasuhiro Katahira and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Special Issue "State-of-the-Art Cancer Immunotherapies-2nd Edition".International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hideaki HasegawaDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Eri SakamotoDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Aruma WatanabeDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Natsuki YamaguchiDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Eri HorioDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Jukito SonodaDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Miu YamagishiDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Satomi MiyakawaDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Fumihiro MurakamiDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Yasuhiro KatahiraDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Izuru MizoguchiDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan.
Takayuki YoshimotoDepartment of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo, 160- 8402, Japan. yoshimot@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0002-2847-0341

Funding

Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan 22K07504
6 · The paper itself

Abstract

Cell-free therapy using the conditioned medium (CM) of mesenchymal stem cells has attracted great interest in regenerative medicine due to its fewer ethical and safety concerns. Recently, we established an immortalized dental pulp stem cell line from human exfoliated deciduous teeth (SHED). Herein, we have investigated the therapeutic potentials of SHED-CM on the peripheral neuropathy of experimental autoimmune neuritis (EAN). This model was established by immunizing mice with the myelin protein zero peptide. Multiple administrations of SHED-CM from the day reaching around the peak of symptoms ameliorated significantly the clinical score with slightly recovered motor function. The administrations upregulated myelin basic protein (MBP) and a critical transcriptional factor for myelination EGR2 and phosphorylation of HGF receptor c-MET, but conversely downregulated the negative regulator c-JUN in the sciatic nerves, suggesting the augmentation of remyelination. Moreover, SHED-CM augmented the proliferation of mouse Schwann cell line IMS32 cells partly depending upon HGF, neuregulin 1, and bFGF. SHED-CM induced phosphorylation of c-MET and neuregulin 1 receptors ErbB2-4. In primary mouse Schwann cells, SHED-CM upregulated EGR2 and MBP and promoted the EGR2-mediated myelination. SHED-CM has potent therapeutic effects on the peripheral neuropathy of EAN by promoting the remyelination of Schwann cells possibly through EGR2 upregulation.

Indexed as

Dental PulpNeuritis, Autoimmune, ExperimentalStem CellsTooth, DeciduousAnimalsCell ProliferationCulture Media, ConditionedDisease Models, AnimalEarly Growth Response Protein 2HumansMesenchymal Stem CellsMicePhosphorylationProto-Oncogene Proteins c-metSchwann CellsSciatic NerveCulture Media, ConditionedEarly Growth Response Protein 2Proto-Oncogene Proteins c-metCell-free therapyEarly growth response gene 2Experimental autoimmune neuritisMesenchymal stem cellsMyelinationSchwann cellsStem cells from human exfoliated deciduous teeth-conditioned media

Identifiers

PMID41188337
PMCPMC12586702

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.